modelDarbepoetinAlfa_1

Diagram of DarbepoetinAlfa_1

Extends from Pharmacolibrary.Drugs.ATC.B.B03XA02_1.

Information

name:DarbepoetinAlfa_1
ATC code:B03XA02_1
route:subcutaneous
compartments:2
dosage:1.5mg
volume of distribution:5.1L
clearance:0.0373l/h/kg
other parameters in model implementation

Darbepoetin alfa is a synthetic analog of erythropoietin used to stimulate erythropoiesis. It is approved for the treatment of anemia associated with chronic kidney disease (CKD) and chemotherapy-induced anemia in cancer patients. It is longer-acting than recombinant human erythropoietin due to additional sialic acid groups.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers after subcutaneous administration.

References

  1. An, G, et al., & Veng-Pedersen, P (2017). Population Pharmacokinetics of Darbepoetin in Infants Following Single Intravenous and Subcutaneous Dosing. Journal of pharmaceutical sciences 106(6) 1644–1649. DOI:10.1016/j.xphs.2017.02.001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28189627

  2. Agoram, B, et al., & Sullivan, JT (2007). Population pharmacokinetics of darbepoetin alfa in healthy subjects. British journal of clinical pharmacology 63(1) 41–52. DOI:10.1111/j.1365-2125.2006.02752.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/16939525

  3. Kawakami, K, et al., & Akizawa, T (2009). Population pharmacokinetics of darbepoetin alpha in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration. European journal of clinical pharmacology 65(2) 169–178. DOI:10.1007/s00228-008-0561-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/18807251

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)